CYP2C19*3 has a premature stop codon in exon 4 and it is biologically plausible that the CYP2C19*3 polymorphism is a modulator of cancer susceptibility; however, we did not find CYP2C19*3 to be associated with ESCC susceptibility in our study population. The gene discussed is CYP2C19; the disease is cancer.